HVCN1 and breast carcinoma: Also, HV1 is involved in different pathologies such as B cell malignancy (Hondares et al., 2014), breast cancer (Wang et al., 2012), and post-ischemic brain injury (Wu, 2014; Yu et al., 2020); consequently, in recent years, HV1 has emerged as a possible pharmacological target (Zhao et al., 2018; Zhang et al., 2022).